Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986340 + Nivolumab + Trifluridine/Tipiracil + Bevacizumab in MSS-CRC
NCT07011550Phase 2Suspended
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2025
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of imzokitug in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2025; status: suspended.
02
Drugs
imzokitug
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07011550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011550.